Home  |  About us  |  Editorial board  |  Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 1091Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

CLINICAL RESEARCH METHODOLOGY

Phase 0 clinical trials in oncology new drug development

Gupta Umesh Chandra, Bhatia Sandeep, Garg Amit, Sharma Amit, Choudhary Vaibhav

Year : 2011| Volume: 2| Issue : 1 | Page no: 13-22

   This article has been cited by
 
1 Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials
Jean-Marie Michot,Lina Benajiba,Laura Faivre,Capucine Baldini,Lelia Haddag,Clement Bonnet,Christophe Massard,Frederic Bigot,Camille Bigenwald,Benjamin Verret,Zo A. P. Thomas,Andrea Varga,Anas Gazzah,Antoine Hollebecque,David Ghez,Julien Lazarovici,Rastilav Balheda,Aurore Jeanson,Sophie Postel-Vinay,Alina Danu,Jean-Charles Soria,Xavier Paoletti,Vincent Ribrag
Investigational New Drugs. 2017;
[Pubmed]  [Google Scholar] [DOI]
2 Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?
Zhe Li,Qin Li,Jun Wu,Manyuan Wang,Junxian Yu
Molecules. 2016; 21(10): 1331
[Pubmed]  [Google Scholar] [DOI]
3 [18F]FLT: An imaging biomarker of tumour proliferation for assessment of tumour response to treatment
Dmitry Soloviev,David Lewis,Davina Honess,Eric Aboagye
European Journal of Cancer. 2012; 48(4): 416
[Pubmed]  [Google Scholar] [DOI]

 

Read this article